2Q26 Earnings Rebound, with CDMO Orders and U.S. Footprint Reinforcing the Growth Inflection Point
AI summary card
2Q26 Earnings Rebound, with CDMO Orders and U.S. Footprint Reinforcing the Growth Inflection Point
JPMorgan maintains its Overweight rating and NT$540 target price for Bora Pharmaceuticals, expecting CDMO backlog, U.S. biologics capacity, and operational recovery to drive medium-term growth.
- 2Q26 revenue reached a record NT$5,889 million, up 21% YoY and 47.2% QoQ; gross margin rose to 41.3% and operating margin to 16.8%.
- CDMO backlog reached a record US$317 million, driven by orders from a large pharmaceutical company, improving revenue visibility for 2H26 and 2027.
- The company completed the acquisition of MacroGenics' Rockville biologics plant, creating synergies with the Baltimore facility to form an end-to-end U.S. biologics CDMO platform.
- The analyst raised 2026-2028 sales forecasts by 2% to 5%, while net profit forecasts remain broadly unchanged due to higher selling and marketing investment.
Report interpretation
Overview
Bora Pharmaceuticals' dual-engine strategy consists of CDMO and specialty pharmaceutical sales, with expanded U.S. manufacturing capabilities serving as a long-term growth lever. The report believes that, after a trough in 2025 caused by integration costs and tariff-related order delays, 2Q26 showed clear signs of recovery in revenue, margins, and order momentum, making 2026 likely to be an operational inflection point.
Core views
CDMO remains the core growth engine. The renewal of the five-year GSK agreement, the partnership with Insilico, and innovative-drug projects from several overseas clients demonstrate continued progress in client expansion and project pipeline development. CHC is not a core element of the company's long-term strategy, but its consolidation made a significant contribution to quarterly revenue growth; excluding acquisition consolidation effects, the analyst estimates the company still achieved approximately 10% organic YoY growth.
Analysis framework
The report updates earnings forecasts based on quarterly results, CDMO backlog, U.S. plant acquisitions, and project-signing progress, and uses DCF valuation to set a December 2027 target price.
Methodology notes
Discounted cash flow valuation
Forecasts the company's free cash flow through 2030 and derives the target price by discounting it using WACC and calculating terminal value with a perpetual growth rate.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- 6472.TWCovered company
- Strengths
- Record CDMO backlog, expanded U.S. biologics capacity, increased partnerships and innovative-drug projects, and improved quarterly margins.
- Weaknesses
- CHC is not a core strategic business; sustaining growth requires higher selling and marketing investment, creating near-term pressure on profits.
- Comparison
- The company is shifting from a Taiwan-centered capacity footprint toward a global CDMO network focused on coordination between Rockville and Baltimore in the United States, to advance its long-term goal of becoming a top-15 global CDMO.
- Risks
- CDMO capacity ramp-up slower than expected, earnings volatility from M&A or financing, and operational pressure from tariffs and a strengthening New Taiwan dollar.
Key data
- 2Q26 RevenueNT$5,889 millionUp 21% YoY and 47.2% QoQ, reaching a record high.
- 2Q26 Gross Margin41.3%Improved from the previous 36.0%.
- 2Q26 Operating Margin16.8%Improved from the previous 10.2%.
- CDMO BacklogUS$317 millionA record level, mainly driven by orders from a large pharmaceutical company.
- CHC Business RevenueNT$824.76 millionRepresenting approximately 14% of group sales.
- 2026-2028 Sales Forecast RevisionRaised by 2% to 5%Reflects stronger-than-expected sales momentum in the CHC business; net profit forecasts remain broadly unchanged.
- Key DCF AssumptionsWACC 10.3%, perpetual growth rate 3%Market risk premium 8.0%, risk-free rate 3.8%, and Beta of 0.9.
Impact & implications
Continued improvement in backlog, capacity utilization, and deal opportunities as expected would support CDMO scaling and margin expansion. Integration of the Rockville and Baltimore capacities should enhance localized manufacturing and biologics service capabilities; if U.S. tariff policies on imported generic drugs are implemented, they may also strengthen the company's long-term competitive advantages.
Risks
- CDMO capacity ramp-up and order conversion may be slower than expected.
- Potential acquisitions may create additional financing needs.
- Reciprocal tariffs and a strengthening New Taiwan dollar may weigh on operating performance.
- M&A integration may cause earnings volatility.
What to watch
- The pace of CDMO backlog conversion into revenue and new orders from major clients.
- Integration of the Rockville and Baltimore facilities, capacity utilization, and progress of biologics CDMO projects.
- CHC consolidation contribution and organic growth excluding acquisition effects.
- Margin improvement in 2H26, selling-expense investment, and net profit delivery.
- Implementation of U.S. tariff policies on imported generic drugs and their impact on orders and demand for localized manufacturing.